Are you Dr. Bastian?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 11 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1275 York Ave
New York, NY 10065Phone+1 212-639-8410- Is this information wrong?
Summary
- Dr. Boris Bastian, MD is a pathologist in New York, New York. He is currently licensed to practice medicine in New York and California. He is affiliated with UCSF Medical Center and is a Professor of Dermatology at UCSF.
Education & Training
Ludwig Maximilian University of Munich Faculty of MedicineClass of 1988
Certifications & Licensure
CA State Medical License 2001 - 2025
NY State Medical License 2010 - 2015
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- Top Doctors: New York Metro Area Castle Connolly, 2012
- America's Top Doctors for Cancer Castle Connolly, 2005-2009, 2011
Publications & Presentations
PubMed
- Amplification of Mutant NRAS in Melanocytic Tumors With Features of Spitz Tumors.Jeffrey M Cloutier, Meng Wang, Swapna S Vemula, Sonia Mirza, Jingly Weier, Jamie D Aquino, Timothy H McCalmont, Philip E LeBoit, Boris C Bastian, Iwei Yeh> ;Modern Pathology. 2024 Mar 10
- Distinct senescence mechanisms restrain progression of dysplastic nevi.Franziska K Lorbeer, Gabrielle Rieser, Aditya Goel, Meng Wang, Areum Oh, Iwei Yeh, Boris C Bastian, Dirk Hockemeyer> ;PNAS Nexus. 2024 Feb 1
- STmut: a framework for visualizing somatic alterations in spatial transcriptomics data of cancer.Limin Chen, Darwin Chang, Bishal Tandukar, Delahny Deivendran, Joanna Pozniak, Noel Cruz-Pacheco, Raymond J Cho, Jeffrey Cheng, Iwei Yeh, Chris Marine, Boris C Bastian...> ;Genome Biology. 2023 Nov 30
- Join now to see all
Press Mentions
Evolution of Melanoma Reveals Opportunities for InterventionJuly 9th, 2018
Correcting a Blind SpotJune 30th, 2018
American Skin Association Announces Abby S. And Howard P. Milstein Innovation Award for Melanoma/Non-Melanoma Skin Cancer ResearchApril 17th, 2018- Join now to see all
Grant Support
- The KIT Signaling Pathway As A Therapeutic Target In MelanomaNational Cancer Institute2011–2012
- The GNAQ Pathway As A Therapeutic Target In Uveal MelanomaNational Cancer Institute2010–2012
- The GNAQ Pathway As A Therapeutic Target In Uveal MelanomaNational Cancer Institute2011
- Biomarker Discovery For The Classification Of MelanomaNational Cancer Institute2010–2011
- Biomarker Discovery For The Classification Of MelanomaNational Cancer Institute2008–2011
- Genetic Expression Of Lentigo Malignant Melanoma - UCSF ConsortiumNational Cancer Institute2007–2009
- Genomic Analysis Of Squamous Cell CarcinomaNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2003–2007
- Genetic Expression Of Lentigo Malignant Melanoma, Proj. 2 - UCSF ConsortiumNational Cancer Institute2005–2006
- Classification Of Ambiguous Melanocytic TumorsNational Cancer Institute2002–2005
Hospital Affiliations
UCSF Medical CenterSan Francisco, California
